Patents by Inventor Randolf Kerschbaumer

Randolf Kerschbaumer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV
    Publication number: 20140335071
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Application
    Filed: April 7, 2014
    Publication date: November 13, 2014
    Applicant: Baxter Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Composition exhibiting a von Willebrand Factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
    Patent number: 8703429
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: April 22, 2014
    Assignee: Baxler Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Composition exhibiting a von Willebrand Factor (vWF) protease activity with the amino acid sequence AAGGILHLELLV
    Patent number: 8703426
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: April 22, 2014
    Assignee: Baxter Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Anti MIF antibodies
    Patent number: 8668909
    Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: March 11, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A., Dyax Corp.
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
  • Procedure for the generation of a high producer cell line for the expression of a recombinant anti-CD34 antibody
    Patent number: 8399249
    Abstract: The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: March 19, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Randolf Kerschbaumer, Petra Boeck-Taferner, Friedrich Scheiflinger
  • Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
    Patent number: 7910094
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: March 22, 2011
    Assignee: Baxter Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • ANTI MIF ANTIBODIES
    Publication number: 20100260768
    Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.
    Type: Application
    Filed: April 26, 2010
    Publication date: October 14, 2010
    Applicants: Baxter International Inc., Baxter Healthcare S.A., Dyax Corp.
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
  • Anti MIF Antibodies
    Publication number: 20090220521
    Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.
    Type: Application
    Filed: December 30, 2008
    Publication date: September 3, 2009
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
  • PROCEDURE FOR THE GENERATION OF A HIGH PRODUCER CELL LINE FOR THE EXPRESSION OF A RECOMBINANT ANTI-CD34 ANTIBODY
    Publication number: 20090221003
    Abstract: The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines.
    Type: Application
    Filed: February 19, 2009
    Publication date: September 3, 2009
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Randolf Kerschbaumer, Petra Boeck-Taferner, Friedrich Scheiflinger
  • COMPOSITION EXHIBITING A VON WILLEBRAND FACTOR (vWF) PROTEASE ACTIVITY COMPRISING A POLYPEPTIDE CHAIN WITH THE AMINO ACID SEQUENCE AAGGILHLELLV
    Publication number: 20090203110
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Application
    Filed: February 12, 2009
    Publication date: August 13, 2009
    Applicant: Baxter Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
    Patent number: 7501117
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: March 10, 2009
    Assignee: Baxter Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • COMPOSITION EXHIBITING A VON WILLEBRAND FACTOR (vWF) PROTEASE ACTIVITY COMPRISING A POLYPEPTIDE CHAIN WITH THE AMINO ACID SEQUENCE AAGGILHLELLV
    Publication number: 20090017467
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Application
    Filed: July 11, 2008
    Publication date: January 15, 2009
    Applicant: Baxter Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV
    Publication number: 20080176312
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Application
    Filed: February 15, 2008
    Publication date: July 24, 2008
    Applicant: Baxter Aktiengesellschaft
    Inventors: Bernhard Laemmle, Helena Elisabeth Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Factor IXa specific antibodies displaying factor VIIIa like activity
    Patent number: 7297336
    Abstract: Ligands such as antibodies that can bind factor IX/factor IXa and increase the procoagulant activity of factor IXa (FIXa), pharmaceutical compositions containing such ligands, methods for treating patients afflicted with blood coagulation with such ligands, and a nucleic acid that encodes, or a cell that expresses such ligands, are provided.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: November 20, 2007
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger
  • Factor IX/factor IXa activating antibodies and antibody derivatives
    Patent number: 7279161
    Abstract: An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.
    Type: Grant
    Filed: March 28, 2005
    Date of Patent: October 9, 2007
    Assignee: Baxter Aktiengesellschaft
    Inventors: Friedrich Scheiflinger, Randolf Kerschbaumer, Falko-Guenter Falkner, Friedrich Dorner, Hans-Peter Schwarz
  • Factor IX/factor IXa activating antibodies and antibody derivatives
    Patent number: 7033590
    Abstract: An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: April 25, 2006
    Assignee: Baxter Aktiengesellschaft
    Inventors: Friedrich Scheiflinger, Randolf Kerschbaumer, Falko-Guenter Falkner, Friedrich Dorner, Hans-Peter Schwarz
  • Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
    Publication number: 20050266528
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Application
    Filed: June 23, 2005
    Publication date: December 1, 2005
    Inventors: Bernhard Laemmie, Helena Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Schelflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Factor IX/factor IXa activating antibodies and antibody derivatives
    Publication number: 20050196397
    Abstract: An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.
    Type: Application
    Filed: March 28, 2005
    Publication date: September 8, 2005
    Applicant: Baxter Aktiengesellschaft
    Inventors: Friedrich Scheiflinger, Randolf Kerschbaumer, Falko-Guenter Falkner, Friedrich Domer, Hans-Peter Schwarz
  • Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
    Patent number: 6926894
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV (SEQ ID NO: 1), vWF cleaving complexes and methods for their production.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: August 9, 2005
    Assignee: Baxter Aktiengesellschaft
    Inventors: Bernhard Laemmle, Helena Elisabeth Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Factor IXa specific antibodies displaying factor VIIIa like activity
    Publication number: 20050058640
    Abstract: Ligands such as antibodies that can bind factor IX/factor IXa and increase the procoagulant activity of factor IXa (FIXa), pharmaceutical compositions containing such ligands, methods for treating patients afflicted with blood coagulation with such ligands, and a nucleic acid that encodes, or a cell that expresses such ligands, are provided.
    Type: Application
    Filed: September 12, 2003
    Publication date: March 17, 2005
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger